A new opinion article published in the New England Journal of Medicine by a group of public health, legal, and medical experts claims the FDA's REMS restrictions on mifepristone make things harder for women seeking medication abortions, despite the pill being beneficial for those seeking them.
These restrictions, the group says, are unfair because they place a burden on women seeking abortions that isn't placed on people seeking medication with similar side effects or risks.
The statement also noted the organization's belief that REMS restrictions are no longer necessary for mifepristone, not only because it's proven itself safe, but because of the "significant benefits" it provides to patients.
As an example, ACOG noted that the death rate associated with medication abortion is still lower than the death rate of women associated with childbirth.
The opinion article published in NEJM also pointed out that lifting some or all of the REMS restrictions could make abortion more accessible for women who live in "rural or medically underserved areas" sometimes referred to as "abortion deserts," where clinics can sometimes be hundreds of miles away.